|
Customer reported that an employee was exposed to blood product from a source patient with a (b)(6) result on a serum sample tested with the alere determine hiv 1/2 ag/ab combo.The exposed employee was not tested with alere determine hiv 1/2 ag/ab combo.The employee was started on (b)(6) as a result of the preliminary (b)(6) result from the source patient.Employee gender, pregnancy status, and outcome were unknown.There is insufficient information to determine if a malfunction occurred.At the time of the event there was no indication of a product malfunction based on the information provided and assessed by alere (b)(4), inc.; however, this mdr is a retrospective filing in response to an fda observation from an fda inspection conducted february 26th to march 2nd, 2018 at alere (b)(4), inc.((b)(4)).
|